Gabather AB (publ) (GABA.ST)
SEK 0.4
(-3.61%)
SEK 0.4
(-3.61%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.93 Million SEK | -56.5% |
| 2022 | 6.75 Million SEK | -56.13% |
| 2021 | 15.39 Million SEK | -52.14% |
| 2020 | 32.16 Million SEK | -30.19% |
| 2019 | 46.07 Million SEK | 153.66% |
| 2018 | 18.16 Million SEK | -62.3% |
| 2017 | 48.17 Million SEK | 38.66% |
| 2016 | 34.74 Million SEK | 157.14% |
| 2015 | 13.51 Million SEK | 47.51% |
| 2014 | 9.16 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 4.14 Million SEK | 41.2% |
| 2024 Q2 | 2.86 Million SEK | -30.96% |
| 2023 FY | 2.93 Million SEK | -56.5% |
| 2023 Q3 | 5.25 Million SEK | -36.27% |
| 2023 Q1 | 10.51 Million SEK | 55.75% |
| 2023 Q2 | 8.24 Million SEK | -21.63% |
| 2023 Q4 | 2.93 Million SEK | -44.08% |
| 2022 Q1 | 12.18 Million SEK | -20.84% |
| 2022 Q3 | 8.51 Million SEK | -18.76% |
| 2022 FY | 6.75 Million SEK | -56.13% |
| 2022 Q4 | 6.75 Million SEK | -20.74% |
| 2022 Q2 | 10.48 Million SEK | -13.94% |
| 2021 FY | 15.39 Million SEK | -52.14% |
| 2021 Q2 | 24.12 Million SEK | -17.7% |
| 2021 Q4 | 15.39 Million SEK | -23.39% |
| 2021 Q3 | 20.09 Million SEK | -16.7% |
| 2021 Q1 | 29.3 Million SEK | -8.87% |
| 2020 Q3 | 34.57 Million SEK | -11.18% |
| 2020 FY | 32.16 Million SEK | -30.19% |
| 2020 Q1 | 42.32 Million SEK | -8.14% |
| 2020 Q4 | 32.16 Million SEK | -6.99% |
| 2020 Q2 | 38.93 Million SEK | -8.01% |
| 2019 Q2 | 11.03 Million SEK | -19.82% |
| 2019 Q1 | 13.76 Million SEK | -24.22% |
| 2019 Q4 | 46.07 Million SEK | 542.72% |
| 2019 FY | 46.07 Million SEK | 153.66% |
| 2019 Q3 | 7.16 Million SEK | -35.04% |
| 2018 FY | 18.16 Million SEK | -62.3% |
| 2018 Q2 | 27.57 Million SEK | -17.8% |
| 2018 Q4 | 18.16 Million SEK | -19.98% |
| 2018 Q3 | 22.69 Million SEK | -17.68% |
| 2018 Q1 | 33.54 Million SEK | -30.38% |
| 2017 FY | 48.17 Million SEK | 38.66% |
| 2017 Q1 | 32.78 Million SEK | -5.64% |
| 2017 Q4 | 48.17 Million SEK | 72.31% |
| 2017 Q3 | 27.96 Million SEK | -6.37% |
| 2017 Q2 | 29.86 Million SEK | -8.92% |
| 2016 Q4 | 34.74 Million SEK | -4.7% |
| 2016 Q2 | 39.07 Million SEK | 214.62% |
| 2016 Q1 | 12.41 Million SEK | -8.1% |
| 2016 FY | 34.74 Million SEK | 157.14% |
| 2016 Q3 | 36.46 Million SEK | -6.68% |
| 2015 Q3 | 14.75 Million SEK | -12.7% |
| 2015 FY | 13.51 Million SEK | 47.51% |
| 2015 Q2 | 16.89 Million SEK | 91.31% |
| 2015 Q1 | 8.83 Million SEK | -3.57% |
| 2015 Q4 | 13.51 Million SEK | -8.4% |
| 2014 Q4 | 9.16 Million SEK | 0.0% |
| 2014 FY | 9.16 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | 94.98% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | 90.822% |
| BioGaia AB (publ) | 2.33 Billion SEK | 99.874% |
| Enzymatica AB (publ) | 125.91 Million SEK | 97.667% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | 91.458% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | 95.983% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | 99.537% |
| Nanexa AB (publ) | 132.25 Million SEK | 97.779% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | 96.768% |
| ODI Pharma AB | 12.27 Million SEK | 76.073% |
| Orexo AB (publ) | 786.6 Million SEK | 99.627% |
| Probi AB (publ) | 1.55 Billion SEK | 99.811% |
| Swedencare AB (publ) | 9.52 Billion SEK | 99.969% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.996% |
| Toleranzia AB | 160.42 Million SEK | 98.169% |
| Vivesto AB | 355.87 Million SEK | 99.175% |